An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer

Copyright © 2024 Cui, Zhang, Lu, Feng, Wu, Zhuo, Zhang and Zhang..

Background: Ovarian cancer (OC) has the highest mortality rate among gynecological malignancies. Current treatment options are limited and ineffective, prompting the discovery of reliable biomarkers. Exosome lncRNAs, carrying genetic information, are promising new markers. Previous studies only focused on exosome-related genes and employed the Lasso algorithm to construct prediction models, which are not robust.

Methods: 420 OC patients from the TCGA datasets were divided into training and validation datasets. The GSE102037 dataset was used for external validation. LncRNAs associated with exosome-related genes were selected using Pearson analysis. Univariate COX regression analysis was used to filter prognosis-related lncRNAs. The overlapping lncRNAs were identified as candidate lncRNAs for machine learning. Based on 10 machine learning algorithms and 117 algorithm combinations, the optimal predictor combinations were selected according to the C index. The exosome-related LncRNA Signature (ERLS) model was constructed using multivariate COX regression. Based on the median risk score of the training datasets, the patients were divided into high- and low-risk groups. Kaplan-Meier survival analysis, the time-dependent ROC, immune cell infiltration, immunotherapy response, and immune checkpoints were analyzed.

Results: 64 lncRNAs were subjected to a machine-learning process. Based on the stepCox (forward) combined Ridge algorithm, 20 lncRNA were selected to construct the ERLS model. Kaplan-Meier survival analysis showed that the high-risk group had a lower survival rate. The area under the curve (AUC) in predicting OS at 1, 3, and 5 years were 0.758, 0.816, and 0.827 in the entire TCGA cohort. xCell and ssGSEA analysis showed that the low-risk group had higher immune cell infiltration, which may contribute to the activation of cytolytic activity, inflammation promotion, and T-cell co-stimulation pathways. The low-risk group had higher expression levels of PDL1, CTLA4, and higher TMB. The ERLS model can predict response to anti-PD1 and anti-CTLA4 therapy. Patients with low expression of PDL1 or high expression of CTLA4 and low ERLS exhibited significantly better survival prospects, whereas patients with high ERLS and low levels of PDL1 or CTLA4 exhibited the poorest outcomes.

Conclusion: Our study constructed an ERLS model that can predict prognostic risk and immunotherapy response, optimizing clinical management for OC patients.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:15

Enthalten in:

Frontiers in immunology - 15(2024) vom: 13., Seite 1228235

Sprache:

Englisch

Beteiligte Personen:

Cui, Yongjia [VerfasserIn]
Zhang, Weixuan [VerfasserIn]
Lu, Wenping [VerfasserIn]
Feng, Yaogong [VerfasserIn]
Wu, Xiaoqing [VerfasserIn]
Zhuo, Zhili [VerfasserIn]
Zhang, Dongni [VerfasserIn]
Zhang, Yichi [VerfasserIn]

Links:

Volltext

Themen:

Biomarkers
CTLA-4 Antigen
Exosome-related lncRNA
Immunotherapy response
Journal Article
Machine learning
Ovarian cancer
Prognosis model
RNA, Long Noncoding
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 27.02.2024

Date Revised 20.03.2024

published: Electronic-eCollection

Citation Status MEDLINE

doi:

10.3389/fimmu.2024.1228235

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM368945626